The Turkish Competition Authority grants individual exemption to a subcontracting agreement concluded with a subcontractor in the same market taking into account localization of the import-dependent insulin industry and sustainability of the quality (Novo Nordisk)

On November 5, 2019, Novo Nordisk Sağlık Ürünleri Ticaret Ltd. Şti. (“Novo Nordisk”) applied to the Turkish Competition Authority (“Authority”) for a negative clearance or an individual exemption with respect to a subcontracting agreement with Abdi İbrahim İlaç San. ve Tic. A.Ş. (“Abdi İbrahim”), a Turkish pharmaceutical company who had previously engaged in another subcontracting agreement with Sanofi Sağlık Ürünleri Ltd. Şti. (“Sanofi”). [1] The agreement with Sanofi, which had been previously granted individual exemption by the Competition Board (“Board”), [2] concerned the manufacturing of certain insulin products by Abdi İbrahim, whereas the new one with Novo Nordisk aimed at the formulation and filling of insulin cartridges, as well as the manufacturing and packaging of insulin injecting pens. The Board

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • ELIG Gürkaynak Attorneys-at-Law (Istanbul)

Quotation

Gönenç Gürkaynak, The Turkish Competition Authority grants individual exemption to a subcontracting agreement concluded with a subcontractor in the same market taking into account localization of the import-dependent insulin industry and sustainability of the quality (Novo Nordisk), 28 July 2020, e-Competitions July 2020, Art. N° 99427

Visites 56

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues